Nivolumab and relatlimab

(Opdualag®)

Nivolumab and relatlimab

Drug updated on 11/15/2023

Dosage FormInjection (intravenous; 240 mg of nivolumab and 80 mg of relatlimab per 20 mL (12 mg and 4 mg per mL))
Drug ClassMonoclonal antibodies
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.

Product Monograph / Prescribing Information

Document TitleYearSource
Opdualag (nivolumab and relatlimab) Prescribing Information. 2022Bristol-Myers Squibb Company Princeton, NJ

Systematic Reviews / Meta-Analyses